Pulse Biosciences to Report First Quarter 2019 Operational Highlights and Financial Results
April 17 2019 - 7:27PM
Business Wire
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy
company bringing to market its proprietary CellFX™ System today
announced that the Company will report first quarter 2019
operational highlights and financial results on Tuesday, April 30,
2019. Pulse Biosciences management will host a conference call at
4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by
dialing (844) 494-0190 (domestic) and (508) 637-5580
(international) using the conference ID# 3466369. The conference
call can also be accessed live on the Investor Relations section of
the Pulse Biosciences website at www.PulseBiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a novel medical therapy company
bringing to market its proprietary CellFX™ System. The Company’s
novel CellFX System provides a precise, non-thermal delivery of
nanosecond duration energy pulses that impact cells in treated
tissue while sparing non-cellular tissue. This unique mechanism of
action disrupts the functions of internal cell structures while
maintaining the outer cell membrane, initiating a cascade of events
within the cell that results in regulated cell death. The novel
characteristics of the Company’s CellFX System has the potential to
significantly benefit patients across multiple medical
applications, including dermatology, the Company’s first planned
commercial application. In pre-clinical studies, Nano-Pulse
Stimulation™ (NPS™) technology platform has demonstrated an ability
to induce immunogenic cell death in several cancer cell lines. The
Company believes its NPS technology platform may play a role in
immuno-oncology as a focal tumor treatment that can initiate an
adaptive immune response. More information can be found
at www.pulsebiosciences.com.
CAUTION: Pulse Biosciences’ CellFX System and Nano-Pulse
Stimulation (NPS) technology are for investigational use only.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190417006021/en/
Investor Relations:Pulse Biosciences, Inc.Brian DowSr.
Vice President and Chief Financial
OfficerIR@PulseBiosciences.comSolebury TroutGitanjali Jain Ogawa,
646-378-2949gogawa@troutgroup.comMedia:Tosk
CommunicationsNadine D. Tosk, 504-453-8344nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024